医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BioBytes™ – IntelliCentrics’ Telehealth Technology Solution Selected by the City of Langfang, China

2020年09月29日 AM01:56
このエントリーをはてなブックマークに追加


 

DALLAS

IntelliCentrics (HKSE: 6819), creator of the healthcare industry’s leading, trusted technology platform, announced that IntelliCentrics’ Beijing, China-headquartered joint venture, Sciencare Technology Co., Ltd., was awarded a contract by the city of Langfang, China. Under this agreement, Sciencare is authorized to provide a localized version of IntelliCentrics’ BioBytes™ to approximately 4.5 million residents.

“BioBytes magic is its ability for patients and providers to benefit equally across the entire continuum of care. In adopting the innovative BioBytes solution, the city of Langfang is providing its community with a trusted healthcare experience, which is what we all want, regardless of where we may be living,” said CEO of IntelliCentrics Group, Mike Sheehan. “Our long history of credentialing physicians, vendors, and medical staff has always been in anticipation of the day we connect patients to our technology platform. Delivering a fully integrated, end-to-end solution built on trust has always been the goal, which is why today is so special.”

Using trust as a technology, IntelliCentrics removes barriers that often result when both accessing and delivering healthcare. “Our mission statement, to use trust to make high-quality healthcare as accessible as a good cup of coffee, is more relevant than ever,” said Sheehan. “With BioBytes, patients now own, collect, and control their health data with the ability to share it with trusted providers of their choice, all within our technology platform. We like to say: Everyone wins with IntelliCentrics.”

IntelliCentrics has seamlessly integrated the highly fragmented credentialing processes required of vendor companies, vendor representatives, nurses, and doctors onto one innovative technology platform. Through this end-to-end solution, supply-side individuals are granted IntelliCentrics SEC³URE Passports identifying them as “trusted” following compliance with both regulations and location-specific policies. SEC³URE Passport holders, along with each location of care on the platform, benefit from the elimination of manual, error-prone, and paper-based processes, expediting trusted status across IntelliCentrics’ 11,000+ locations of care worldwide, all while saving nearly 90% in time and costs.

About IntelliCentrics

With a mission to use trust to make high-quality healthcare as accessible as a good cup of coffee, IntelliCentrics created SEC³URE Ethos. Built on three core principles – transparency, neutrality, and independence, the SEC³URE Ethos platform is relied on by more than 11,000 locations of care worldwide to ensure mutual trust between patients, doctors, vendor representatives and healthcare companies. To learn more about the world’s largest trusted healthcare technology platform, visit www.intellicentrics.com. IntelliCentrics is publicly traded on the Stock Exchange of Hong Kong Limited under the stock code 6819.

About Beijing Sciencare Technology Co., Ltd.

Founded in March 2018 as a joint venture with IntelliCentrics Global Holdings Ltd., Sciencare is a healthcare technology business pioneering the development of a healthcare technology platform in China and is committed to providing patients with genuine and reliable healthcare services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200928005643/en/

CONTACT

Hope Runyan

(469) 257-3810

Hope.Runyan@edelman.com

TimeLine: ,

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表